172 related articles for article (PubMed ID: 26479122)
1. Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
Fawaz CN; Makki IS; Kazan JM; Gebara NY; Andary FS; Itani MM; El-Sayyed M; Zeidan A; Quartarone A; Darwish H; Mondello S
Expert Rev Proteomics; 2015; 12(6):637-50. PubMed ID: 26479122
[TBL] [Abstract][Full Text] [Related]
2. Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients.
Singh V; Tripathi A; Dutta R
Proteomics; 2019 Aug; 19(16):e1800335. PubMed ID: 31119864
[TBL] [Abstract][Full Text] [Related]
3. Commentary on "Relationship between miRNA-21, miRNA-155, and miRNA-182 expression and inflammatory factors in cerebrospinal fluid from patients with multiple sclerosis".
Kumar N; Rauf SA; Riya ; Arbab S
Clin Neurol Neurosurg; 2024 Jan; 236():108054. PubMed ID: 38041985
[TBL] [Abstract][Full Text] [Related]
4. Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis.
Chase Huizar C; Raphael I; Forsthuber TG
Cell Immunol; 2020 Dec; 358():104219. PubMed ID: 33039896
[TBL] [Abstract][Full Text] [Related]
5. The role of miRNAs in multiple sclerosis pathogenesis, diagnosis, and therapeutic resistance.
Doghish AS; Elazazy O; Mohamed HH; Mansour RM; Ghanem A; Faraag AHI; Elballal MS; Elrebehy MA; Elesawy AE; Abdel Mageed SS; Mohammed OA; Nassar YA; Abulsoud AI; Raouf AA; Abdel-Reheim MA; Rashad AA; Elawady AS; Elsisi AM; Alsalme A; Ali MA
Pathol Res Pract; 2023 Nov; 251():154880. PubMed ID: 37832353
[TBL] [Abstract][Full Text] [Related]
6. Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches.
Jafari A; Babajani A; Rezaei-Tavirani M
Biomark Insights; 2021; 16():11772719211013352. PubMed ID: 34017167
[TBL] [Abstract][Full Text] [Related]
7. Proteomics in orthopedic research: Recent studies and their translational implications.
Li G; Stampas A; Komatsu Y; Gao X; Huard J; Pan S
J Orthop Res; 2024 Jun; ():. PubMed ID: 38897819
[TBL] [Abstract][Full Text] [Related]
8. A Birth Year Cohort and What It Can Reveal About Lipid Mediators as Putative Biomarkers of Progression in Multiple Sclerosis.
Rotstein D; Schneider R
Neurology; 2023 Aug; 101(5):197-198. PubMed ID: 37290973
[No Abstract] [Full Text] [Related]
9. Identifying the biomarkers of multiple sclerosis based on non-coding RNA signature.
Sheng WH; Sheng KT; Zhao YX; Li H; Zhou JL; Yao HY; Li XH
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3635-42. PubMed ID: 26502853
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
Ahlbrecht J; Martino F; Pul R; Skripuletz T; Sühs KW; Schauerte C; Yildiz Ö; Trebst C; Tasto L; Thum S; Pfanne A; Roesler R; Lauda F; Hecker M; Zettl UK; Tumani H; Thum T; Stangel M
Mult Scler; 2016 Aug; 22(9):1202-14. PubMed ID: 26493127
[TBL] [Abstract][Full Text] [Related]
11. Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.
Honce JM; Nagae L; Nyberg E
Mult Scler Int; 2015; 2015():809252. PubMed ID: 26483978
[TBL] [Abstract][Full Text] [Related]
12. Cancer specific risk in multiple sclerosis patients.
Kyritsis AP; Boussios S; Pavlidis N
Crit Rev Oncol Hematol; 2016 Feb; 98():29-34. PubMed ID: 26481954
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of neuropathic pain in early multiple sclerosis.
Heitmann H; Biberacher V; Tiemann L; Buck D; Loleit V; Selter RC; Knier B; Tölle TR; Mühlau M; Berthele A; Hemmer B; Ploner M
Mult Scler; 2016 Aug; 22(9):1224-30. PubMed ID: 26480924
[TBL] [Abstract][Full Text] [Related]
14. In Vivo Quantification of Inflammation in Experimental Autoimmune Encephalomyelitis Rats Using Fluorine-19 Magnetic Resonance Imaging Reveals Immune Cell Recruitment outside the Nervous System.
Zhong J; Narsinh K; Morel PA; Xu H; Ahrens ET
PLoS One; 2015; 10(10):e0140238. PubMed ID: 26485716
[TBL] [Abstract][Full Text] [Related]
15. Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis.
Jonkman LE; Rosenthal DM; Sormani MP; Miles L; Herbert J; Grossman RI; Inglese M
PLoS One; 2015; 10(10):e0129380. PubMed ID: 26485710
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of exercise intervention programs on cognition in people suffering from multiple sclerosis, stroke and Parkinson's disease: A systematic review and meta-analysis of current evidence.
Kalron A; Zeilig G
NeuroRehabilitation; 2015; 37(2):273-89. PubMed ID: 26484519
[TBL] [Abstract][Full Text] [Related]
17. Changes and variability of proton density and T1 relaxation times in early multiple sclerosis: MRI markers of neuronal damage in the cerebral cortex.
Gracien RM; Reitz SC; Hof SM; Fleischer V; Zimmermann H; Droby A; Steinmetz H; Zipp F; Deichmann R; Klein JC
Eur Radiol; 2016 Aug; 26(8):2578-86. PubMed ID: 26494641
[TBL] [Abstract][Full Text] [Related]
18. A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis Patients.
Ligocki AJ; Rivas JR; Rounds WH; Guzman AA; Li M; Spadaro M; Lahey L; Chen D; Henson PM; Graves D; Greenberg BM; Frohman EM; Ward ES; Robinson W; Meinl E; White CL; Stowe AM; Monson NL
ASN Neuro; 2015; 7(5):. PubMed ID: 26489686
[TBL] [Abstract][Full Text] [Related]
19. Sodium channel blockers for neuroprotection in multiple sclerosis.
Yang C; Hao Z; Zhang L; Zeng L; Wen J
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010422. PubMed ID: 26486929
[TBL] [Abstract][Full Text] [Related]
20. Mucosal-Associated Invariant T Cells in Multiple Sclerosis: The Jury is Still Out.
Treiner E; Liblau RS
Front Immunol; 2015; 6():503. PubMed ID: 26483793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
